Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
TTABV Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of transformative therapies for patients suffering from severe diseases with limited treatment options, primarily in oncology and immunology. Leveraging our proprietary [e.g., MultiModal Antibody Therapeutics™] platform, we aim to engineer next-generation medicines that can address complex biological targets. Our team of world-class scientists and clinicians is driven by a sense of urgency and a deep commitment to improving human health. We are focused on advancing our robust pipeline of innovative drug candidates through rigorous clinical development and towards market approval.
The headquarters serves as the primary center for research and development, corporate strategy, business development, and global administrative operations.
Features state-of-the-art laboratory spaces, advanced research equipment, collaborative open-plan offices, and sustainable building design elements.
TTABV fosters a dynamic, inclusive, and science-driven work culture. Emphasis is placed on collaboration, innovation, continuous learning, and a shared mission to impact patient lives. Employees experience a fast-paced environment with opportunities for significant professional growth.
Its Cambridge location provides unparalleled access to a rich ecosystem of academic institutions (like MIT and Harvard), research hospitals, venture capital, and a dense talent pool of experienced biotech professionals.
TTABV Biotherapeutics operates with a global mindset, conducting clinical trials across North America, Europe, and select sites in Asia-Pacific. Our research collaborations and strategic partnerships span multiple continents, enabling us to access diverse scientific expertise and patient populations to advance our therapeutic programs worldwide.
75 Binney Street
Cambridge
Massachusetts
USA
Address: 400 Oyster Point Blvd, Suite 250, South San Francisco, CA 94080
To manage and expand clinical trial activities in the Western US, foster relationships with West Coast research institutions and partners, and recruit specialized talent.
Address: Gubelstrasse 11, 6300 Zug, Switzerland
To navigate European regulatory pathways, coordinate multi-national clinical trials within Europe, and prepare for potential market entry and commercialization in key European markets.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, TTABV Biotherapeutics' leadership includes:
TTABV Biotherapeutics has been backed by several prominent investors over the years, including:
In the past year, TTABV Biotherapeutics has strategically expanded its executive leadership by appointing a new Chief Commercial Officer to prepare for potential product launches and has seen a planned transition in the Head of Regulatory Affairs.
Discover the tools TTABV Biotherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
TTABV Biotherapeutics typically uses a standard email format combining the first initial with the full last name of the employee, followed by the company domain.
f[last]@ttabvbiotherapeutics.com (e.g., evance@ttabvbiotherapeutics.com)
Format
sgriggs@ttabvbiotherapeutics.com
Example
90%
Success rate
BioWorld • May 10, 2024
TTABV Biotherapeutics announced compelling results from its Phase 2b study of TTB-101, an investigational therapy for lupus nephritis. The data, presented at the European Congress of Rheumatology (EULAR), showed statistically significant improvements in renal response rates and key secondary endpoints....more
Endpoints News • February 20, 2024
TTABV Biotherapeutics successfully closed a $150 million Series C financing round. The funding will be used to advance its lead oncology candidate, TTB-205, into pivotal Phase 3 trials and progress its earlier-stage pipeline of novel immunotherapies....more
Company Press Release • November 06, 2023
At the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting, TTABV Biotherapeutics presented preclinical data elucidating the unique mechanism of action of TTB-205, its lead immuno-oncology candidate. The findings demonstrate potent tumor cell killing and immune activation....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including TTABV Biotherapeutics, are just a search away.